← Studies & programmes
Emerging treatmentsPhase 1/2 study in people — safety and possible benefitResearch, not an established treatment

UKT-CART19.1: a CAR-T study in autoimmune diseases including MS, Tübingen

Published by MyelinWatch:

UKT-CART19.1 (Tübingen) CAR-T study in autoimmune diseases including MS · University Hospital Tübingen plans to test UKT-CART19.1 in adults with seven relapsed or treatment-resistant autoimmune diseases, one of which is multiple sclerosis (MS). The treatment is CAR-T cells: the person's own T cells, a type of immune cell, are modified in the laboratory to find CD19, a marker on B cells, another type of immune cell that takes part in MS inflammation. They are given back as a single infusion. The Phase 1/2 study is mainly about safety.

What is being studied

University Hospital Tübingen plans to test UKT-CART19.1 in adults with seven relapsed or treatment-resistant autoimmune diseases, one of which is multiple sclerosis (MS). The treatment is CAR-T cells: the person's own T cells, a type of immune cell, are modified in the laboratory to find CD19, a marker on B cells, another type of immune cell that takes part in MS inflammation. They are given back as a single infusion. The Phase 1/2 study is mainly about safety.

Research stage

Phase 1/2 study in people — safety and possible benefit

The study is not yet accepting participants.

What we know so far

ClinicalTrials.gov first posted the study on 12 November 2026 and lists it as not yet accepting participants, with an estimated start in January 2027 and an estimated 36 participants across all diseases; it does not say how many will have MS. The EU clinical trials register shows authorisation in Germany on 14 August 2026. Both records list one centre, in Tübingen. No results are posted, and neither record shows that anyone has been enrolled or treated.

What this means for patients today

This is a study, not an available treatment for MS, and it has not been shown to work or to be safe in MS. It is not yet accepting participants. Neither record lists a site in Greece, so it is not an established route to treatment for people in Greece. Eligibility is decided by the study team, whose contacts are in the registry.

Treatment or approach
UKT-CART19.1: CAR-T cells made from the person's own T cells, tested in several autoimmune diseases including MS
How it is intended to work
CD19-directed CAR T cells made from the person's own T cells, given as a single infusion
Where the study is running
One centre, in Tübingen, Germany; neither record lists a site in Greece.
Source: ClinicalTrials.gov — official clinical-trial registry ↗Source: EU Clinical Trials Information System — 2024-519491-60-00, authorised in Germany ↗
Published by MyelinWatch
Last substantive MyelinWatch update

Programme updates — newest research developments first

  1. Registered Phase 1/2 study; not yet accepting participants; start estimated for January 2027Research event/source date:

    UKT-CART19.1: a CAR-T study in autoimmune diseases including MS was registered in Tübingen

    ClinicalTrials.gov first posted NCT07932262 on 12 November 2026. The sponsor is University Hospital Tübingen in Germany. This is a single-centre, open-label Phase 1/2 study with one treatment group. It tests UKT-CART19.1, CAR-T cells made from the person's own T cells and aimed at CD19, a marker on B cells. The same treatment, given as one infusion, is tested in adults aged 18 to 80 with seven relapsed or treatment-resistant autoimmune diseases, one of which is multiple sclerosis (MS). People with MS must have had recent disease activity (a relapse, worsening or new MRI activity in the previous 24 months) and must not have responded to at least two high-potency MS medicines (category 3 in the German guideline). The registry estimates 36 participants in total for all diseases and does not say how many will have MS. The main outcome is safety over 6 months. The EU clinical trials register (CTIS) shows authorisation in Germany on 14 August 2026. ClinicalTrials.gov lists the study as not yet accepting participants, with an estimated start in January 2027.

    Source: ClinicalTrials.gov — official clinical-trial registry ↗Source: EU Clinical Trials Information System — 2024-519491-60-00, authorised in Germany on 14 August 2026 ↗